Efficacy of combination therapy of sitagliptin and low-dose glimepiride in patients with type 2 diabetes mellitus inadequately controlled with high-dose glimepiride

Efficacy of combination therapy of sitagliptin and low-dose glimepiride in patients with type 2 diabetes mellitus inadequately controlled with high-dose glimepiride - Efficacy of combination therapy of sitagliptin and low-dose glimepiride

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013827

Enrollment

Registered

2014-04-30

Start date

2011-01-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type2 diabetes

Interventions

Subjects with uncontrolled T2DM in high-dose(3-6mg) glimepiride were received reduced dose of glimepiride 0.5 mg/day,at the addition of 50 mg/day sitagliptin.We evaluated HbA1c at baseline and after

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligible subjects were treated with glimepiride at dose of 3-6mg/day (with or without Metformin,alpha-glucosidase inhibitor, and Thiazolidinedione) for at least 3 months and HbA1c level > =6.9%.

Exclusion criteria

Exclusion criteria: Subjects with type 1 diabetes mellitus, secondary diabetes, diabetic nephropathy stage 4-5, malignancy or other severe conditions, aged < 20, were excluded.

Design outcomes

Primary

Measure	Time frame
Change of HbA1c	—

Countries

Japan

Contacts

Public ContactRieko Umayahara

Shizuoka General Hospital Center for Endocrinology and Metabolism

fwkh7040spring@yahoo.co.jp054-247-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026